This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sanofi-Aventis Revenue Swells

Sanofi-Aventis (SNY - Get Report) said Monday that full-year sales rose 9% to $33 billion as strong gains from its vaccine business and several signature products were partly offset by generic competition for several other drugs.

Fourth-quarter sales gained 5% to $8.46 billion.

The French company won't issue its earnings results until Feb. 24, although it said last year's earnings per share, excluding one-time items, should be about 25% higher than for 2004.

Meanwhile, many analysts are paying more attention to two big upcoming events that will have a major impact during the rest of the decade than to last year's and last quarter's sales and earnings.

Next month, the Food and Drug Administration is supposed to rule on Acomplia, a proposed treatment for obesity and addiction to smoking that has made some analysts giddy with excitement.

In April, Sanofi-Aventis will ask a U.S. court to prevent another company from selling a cheap, generic copy of the anticoagulant Plavix, the company's second-biggest product and the biggest-selling drug for its marketing partner Bristol-Myers Squibb (BMY).

"Each [event] has the ability to impact shares significantly," says Tim Anderson, of Prudential Equity Group, in a research report issued last week.

A court defeat for the generic challenger means five more years of patent protection for a drug that produced $2.45 billion of sales for Sanofi-Aventis and $3.82 billion for Bristol-Myers Squibb. The FDA recently allowed the Canadian company Apotex to sell generic Plavix, but Anderson and other analysts doubt Apotex will act until the court has ruled, or unless it settles with Sanofi-Aventis.

A favorable FDA decision for Acomplia means the drug could be on the market during the second quarter. "Acomplia is the most promising late-stage pipeline product" among European drug companies, says Gbola Amusa, of Sanford C. Bernstein, in a research report published several days before Sanofi-Aventis issued in earnings report. "The weight is over."
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
SNY $41.10 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs